Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies.

Gabriela Henrykowska, Dorota Bartusik-Aebisher, Klaudia Dynarowicz, Tamil Selvan Ramesh, Barbara Smolak, David Aebisher

Abstract readReview

In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gabriela HenrykowskaDepartment of Epidemiology and Public Health, Faculty of Medicine, Medical University of Lodz, T. Kosciuszki 4, 90-419 Lodz, Poland.ORCID 0000-0002-9277-0875

Dorota Bartusik-AebisherDepartment of Biochemistry and General Chemistry, Faculty of Medicine, University of Rzeszów, 35-310 Rzeszów, Poland.ORCID 0000-0002-5557-5464

Klaudia DynarowiczDepartment of Biochemistry and General Chemistry, Faculty of Medicine, University of Rzeszów, 35-310 Rzeszów, Poland.ORCID 0000-0001-6851-5869

Tamil Selvan RameshMedical Science Club, Faculty of Medicine, University of Rzeszów, 35-310 Rzeszów, Poland.ORCID 0009-0004-1752-9047

Barbara SmolakDepartment of Diagnostic Imaging and Nuclear Medicine, Faculty of Medicine, University of Rzeszów, 35-310 Rzeszów, Poland.

David AebisherDepartment of Photomedicine and Physical Chemistry, Faculty of Medicine, University of Rzeszów, 35-959 Rzeszów, Poland.ORCID 0000-0002-2661-6570

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cetuximab and panitumumab are anti-EGFR monoclonal antibodies widely used for the treatment of colorectal cancers. However, due to various mechanisms of resistance to these targeted therapies, the patients' responses vary. These resistances remain a major obstacle in treatment and overcoming them has become a key emphasis of current therapeutic strategies. Intrinsic and acquired resistance often lead to reactivation of downstream signaling pathways, mainly the RAS-RAF-MEK-ERK (MAPK pathway) and PI3K-AKT axes. Prior existing mutations in

Indexed as

acquired resistanceanti-EGFRcetuximabcolorectal cancercombination strategiesctDNAintrinsic resistanceMAPK pathwaypanitumumabPI3K-AKT-mTOR axis

Identifiers

PMID42515723

DOI10.3390/ph19071041

PMCPMC13415011

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.